ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES

摘要

This invention relates to the detection of patients at risk for developing integrin antagonist/agonist mediated disease states. This invention also relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies (DDABs) that bind to integrins in the presence of an integrin agonist and/or antagonist, and to procedures for identifying integrin antagonists/agonists that are less prone to elicit integrin antagonist/agonist mediated disease states. This invention also relates to procedures which increase the recovery of integrin-directed antibodies in body fluids, resulting in an increased sensitivity and specificity of DDAB detection assays and to procedures for treating blood samples, which dissociate antibodies to GPIIb/IIIa from the platelet surface, thereby increasing the recovery from the platelet supernatant. This invention also relates to the use of different GPIIb/IIIa preparations to identify patients at risk for early-onset thrombocytopenia upon treatment with GPIIb/IIIa antagonist/agonists, thereby increasing the specificity of antibody detection.